222 related articles for article (PubMed ID: 28542862)
21. R-CHOP appears to be the best first-line treatment for second primary diffuse large B cell lymphoma: a cancer registry study.
Systchenko T; Defossez G; Guidez S; Laurent C; Puyade M; Debiais-Delpech C; Dreyfus B; Machet A; Leleu X; Delwail V; Ingrand P
Ann Hematol; 2020 Jul; 99(7):1605-1613. PubMed ID: 32451709
[TBL] [Abstract][Full Text] [Related]
22. Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study.
Wu JQ; Song YP; Su LP; Zhang MZ; Li W; Hu Y; Zhang XH; Gao YH; Niu ZX; Feng R; Wang W; Peng JW; Li XL; Ouyang XN; Wu CP; Zhang WJ; Zeng Y; Xiao Z; Liang YM; Zhuang YZ; Wang JS; Sun ZM; Bai H; Cui TJ; Feng JF
Chin Med J (Engl); 2018 Aug; 131(15):1767-1775. PubMed ID: 30058572
[TBL] [Abstract][Full Text] [Related]
23. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
24. The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B-cell lymphoma.
Habbous S; Guo H; Beca J; Dai WF; Isaranuwatchai W; Cheung M; Chan KKW
Cancer Med; 2020 Oct; 9(19):7072-7082. PubMed ID: 32794362
[TBL] [Abstract][Full Text] [Related]
25. Role of radiation therapy in primary breast diffuse large B-cell lymphoma in the Rituximab era: a SEER database analysis.
Liu PP; Wang KF; Jin JT; Bi XW; Sun P; Wang Y; Yang H; Li ZM; Jiang WQ; Xia Y
Cancer Med; 2018 May; 7(5):1845-1851. PubMed ID: 29624913
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era.
Gutierrez A; Bento L; Diaz-Lopez A; Barranco G; Garcia-Recio M; Lopez-Guillermo A; Dlouhy I; Rovira J; Rodriguez M; Sanchez Pina JM; Baile M; Martín A; Novelli S; Sancho JM; García O; Salar A; Bastos-Oreiro M; Rodriguez-Salazar MJ; Fernandez R; de la Cruz F; Queizan JA; González de Villambrosia S; Cordoba R; López A; Luzardo H; García D; Sastre-Serra J; Garcia JF; Montalban C; Cabanillas F; Rodríguez J
Eur J Haematol; 2020 May; 104(5):400-408. PubMed ID: 31804029
[TBL] [Abstract][Full Text] [Related]
27. Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era.
Hunter BD; Herr M; Meacham PJ; Barlaskar F; Evans AG; Burack WR; Liesveld JL; Becker MW; Milner LA; Constine LS; Dhakal S; Barr PM; Friedberg JW; Casulo C
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):145-151. PubMed ID: 27998707
[TBL] [Abstract][Full Text] [Related]
28. Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: a population-based cohort study.
Bilmon IA; Ashton LJ; Le Marsney RE; Dodds AJ; O'Brien TA; Wilcox L; Nivison-Smith I; Daniels B; Vajdic CM;
Bone Marrow Transplant; 2014 May; 49(5):691-8. PubMed ID: 24535126
[TBL] [Abstract][Full Text] [Related]
29. [Clinical features and outcomes of newly diagnosed follicular lymphoma concurrent with diffuse large B-cell lymphoma component].
Lin ZJ; Zha J; Yi SH; Li ZF; Ping LY; He XH; Yu HF; Zheng Z; Xu W; Chen FL; Xie Y; Chen BY; Zhang HL; Wang L; Ding KY; Li WY; Yang HY; Zhao WL; Qiu LG; Li ZM; Song YQ; Xu B
Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):456-462. PubMed ID: 35968587
[No Abstract] [Full Text] [Related]
30. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era.
Hosein PJ; Maragulia JC; Salzberg MP; Press OW; Habermann TM; Vose JM; Bast M; Advani RH; Tibshirani R; Evens AM; Islam N; Leonard JP; Martin P; Zelenetz AD; Lossos IS
Br J Haematol; 2014 May; 165(3):358-63. PubMed ID: 24467658
[TBL] [Abstract][Full Text] [Related]
31. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma.
Hyo R; Tomita N; Takeuchi K; Aoshima T; Fujita A; Kuwabara H; Hashimoto C; Takemura S; Taguchi J; Sakai R; Fujita H; Fujisawa S; Ogawa K; Motomura S; Suzuki R; Ishigatsubo Y
Hematol Oncol; 2010 Mar; 28(1):27-32. PubMed ID: 19358143
[TBL] [Abstract][Full Text] [Related]
32. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA.
Ren J; Asche CV; Shou Y; Galaznik A
J Comp Eff Res; 2019 Apr; 8(6):393-402. PubMed ID: 30855175
[TBL] [Abstract][Full Text] [Related]
33. Role of consolidative radiation therapy for patients with mediastinal diffuse large B-cell lymphoma in the rituximab era.
Sert F; Kamer S; Saydam G; Anacak Y
J Cancer Res Ther; 2018; 14(6):1397-1402. PubMed ID: 30488862
[TBL] [Abstract][Full Text] [Related]
34. Risk and outcome of acute myeloid leukaemia among survivors of primary diffuse large B-cell lymphoma: a retrospective observational study based on SEER database.
Du Y; Wang Y; Li Q; Chang X; Zhang H; Xiao M; Xing S
BMJ Open; 2022 Sep; 12(9):e061699. PubMed ID: 36581968
[TBL] [Abstract][Full Text] [Related]
35. Increased risk of second primary malignancies following uterine cancer: a population-based study in Taiwan over a 30-year period.
Lee KD; Chen CY; Huang HJ; Wang TY; Teng D; Huang SH; Lai CH; Chen MC
BMC Cancer; 2015 May; 15():393. PubMed ID: 25957789
[TBL] [Abstract][Full Text] [Related]
36. Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study.
Spanogle JP; Clarke CA; Aroner S; Swetter SM
J Am Acad Dermatol; 2010 May; 62(5):757-67. PubMed ID: 20223559
[TBL] [Abstract][Full Text] [Related]
37. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.
Kridel R; Telio D; Villa D; Sehn LH; Gerrie AS; Shenkier T; Klasa R; Slack GW; Tan K; Gascoyne RD; Connors JM; Savage KJ
Br J Haematol; 2017 Jan; 176(2):210-221. PubMed ID: 27739058
[TBL] [Abstract][Full Text] [Related]
38. Mutual Risks of Cutaneous Melanoma and Specific Lymphoid Neoplasms: Second Cancer Occurrence and Survival.
Herr MM; Schonfeld SJ; Dores GM; Withrow DR; Tucker MA; Curtis RE; Morton LM
J Natl Cancer Inst; 2018 Nov; 110(11):1248-1258. PubMed ID: 29659938
[TBL] [Abstract][Full Text] [Related]
39. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
40. The beneficial effect of Escalated-R-CHOP-21 for the treatment of diffuse large B-cell lymphoma in elderly male patients: A propensity-matched cohort study.
He HX; Gao Y; Bai B; Wang XX; Li JB; Huang C; Mao JY; Ping LQ; Rong QX; He YX; Huang H; Cai QQ; Li ZM; Jiang WQ; Huang HQ
Cancer Med; 2021 Nov; 10(21):7650-7664. PubMed ID: 34581023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]